Skip to main content

Table 3 Comparison between scores obtained with the Motola’s rating system and the Ahlqvist-Rastad’s rating system

From: Assessment of the therapeutic value of new medicines marketed in Australia

  Ahlqvist-Rastad’s rating system
Motola’s rating system Added therapeutic value Similar therapeutic value Inferior therapeutic value Uncertain therapeutic value Total
Important 7 (36.8%) - - - 7
Moderate 9 (47.4%) 3 (12.0%) * - 5 (50.0%) ** 17
Modest 3 (15.8%) - - 1 (10.0%) *** 4
Pharmacological - 2 (8.0%) 2 (40.0%) 2 (20.0%) 6
Technological - 20 (80.0%) 3 (60.0%) 2 (20.0%) 25
TOTAL 19 25 5 10 59
  1. * Abatacept, fulvestrant and pregabalin.
  2. ** Maraviroc, natalizumab, nitric oxide, pegvisomant and sunitinib.
  3. *** Palifermin.